Corporate ActionAug 10, 2026, 04:24 PM
Arcadia Biosciences Proposes Reverse Stock Split to Meet Nasdaq Rule
AI Summary
Arcadia Biosciences, Inc. will hold its 2026 Annual Meeting of Stockholders on September 10, 2026, to vote on several key proposals. The company is seeking approval for a reverse stock split, with a ratio between 1-for-2 and 1-for-10, to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a deficiency letter on August 4, 2026. Stockholders will also vote on the potential issuance of common stock from Series A-1 Preferred Investment Options, which could generate approximately $3.5 million, and the approval of a new 2026 Omnibus Equity Incentive Plan.
Key Highlights
- Reverse stock split ratio proposed: 1-for-2 to 1-for-10.
- Reverse stock split must be effected by June 30, 2027.
- Nasdaq minimum bid price requirement is $1.00.
- Deficiency letter from Nasdaq received on August 4, 2026.
- 180-day compliance period until February 1, 2027.
- Potential $3.5 million gross proceeds from Series A-1 Options exercise.
- Annual Meeting of Stockholders scheduled for September 10, 2026.
- Record date for voting was July 29, 2026.
Price Impact
More from RKDA